GNOM vs IHI

Key Takeaways

• GNOM targets the genomics and biotechnology subsector through the Solactive Genomics Index, emphasizing gene editing, sequencing, and genetic therapies, while IHI tracks the Dow Jones U.S. Select Medical Equipment Index for broad exposure to U.S. medical device manufacturers and distributors.
• GNOM maintains approximately 50 holdings with heavy concentration in biotechnology and life sciences companies, whereas IHI holds about 46 securities focused almost entirely on health care equipment.
• IHI offers a lower expense ratio of 0.37% compared to GNOM's 0.50%, providing a cost advantage for long-term investors seeking medical device exposure.
• Both ETFs employ passive strategies with distinct thematic tilts: GNOM delivers higher-risk, higher-volatility exposure to emerging genomic technologies, while IHI provides more stable positioning within established medical equipment firms.
• GNOM exhibits greater international diversification within its holdings, whereas IHI maintains a strict focus on U.S.-listed companies in the medical devices space.
• Structural differences position GNOM for growth-oriented investors comfortable with biotechnology volatility, while IHI suits those seeking defensive healthcare exposure through tangible medical products.

Introduction

Investors evaluating specialized healthcare exposure often compare thematic biotechnology funds with medical device sector vehicles. The Global X Genomics & Biotechnology ETF (GNOM) and the iShares U.S. Medical Devices ETF (IHI) do not compete directly but offer differentiated approaches within the broader health care sector. GNOM provides targeted access to genomic innovation, while IHI delivers diversified exposure to established medical equipment companies. This comparison highlights structural distinctions that help investors align portfolios with specific risk tolerances and thematic preferences amid ongoing advancements in healthcare technology.

Global X Genomics & Biotechnology ETF (GNOM) Overview

The Global X Genomics & Biotechnology ETF (GNOM) seeks to track the Solactive Genomics Index, which focuses on companies deriving significant revenue from gene editing, genomic sequencing, genetic medicine, computational genomics, and biotechnology. The fund holds approximately 50 securities and maintains a total expense ratio of 0.50%. Top holdings typically include Moderna (MRNA), Twist Bioscience (TWST), 10x Genomics (TXG), Guardant Health (GH), and Illumina (ILMN). Sector allocation concentrates heavily in pharmaceuticals, biotechnology, and life sciences at roughly 86%, with smaller weights in health care equipment and services. As a passive, non-diversified thematic ETF, GNOM rebalances periodically to maintain index alignment and offers global exposure within its mandate.

iShares U.S. Medical Devices ETF (IHI) Overview

The iShares U.S. Medical Devices ETF (IHI) tracks the Dow Jones U.S. Select Medical Equipment Index, which measures performance of U.S. equities in the medical equipment sector, including manufacturers and distributors of devices such as imaging systems, prosthetics, and monitoring equipment. The fund holds approximately 46 securities with a total expense ratio of 0.37%. Prominent holdings generally feature Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Stryker (SYK), Becton Dickinson (BDX), and Dexcom (DXCM). Nearly all assets (over 99%) reside in health care equipment. Structured as a passive ETF, IHI follows a rules-based index methodology with quarterly rebalancing and maintains a U.S.-centric focus for liquidity and regulatory alignment.

Industry and Thematic Backdrop

The healthcare sector continues to benefit from technological innovation, aging demographics, and evolving regulatory frameworks supporting precision medicine and device adoption. Genomic advancements drive interest in therapies with high growth potential, while medical devices benefit from steady demand for diagnostic and surgical tools amid hospital capital spending cycles. Capital flows into healthcare remain resilient, though interest rate environments and reimbursement policies introduce variability. Both ETFs face sector-specific risks including regulatory changes, intellectual property challenges, and competition, yet they position investors differently across the healthcare value chain—from cutting-edge research to commercialized equipment.

Performance and Positioning Comparison

In recent market cycles, GNOM has shown elevated volatility tied to biotechnology earnings announcements and clinical trial outcomes, reflecting its concentrated exposure to early-stage genomic firms. IHI has demonstrated more measured movements aligned with broader healthcare equipment demand and capital expenditure trends. Relative positioning favors GNOM for investors seeking amplified exposure to innovation-driven rotations, while IHI offers steadier participation in defensive healthcare segments less sensitive to short-term biotech news. Over broader periods, differences in holdings and sector weights have led to divergent responses to macroeconomic shifts such as interest rate expectations and healthcare policy developments.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to discover additional opportunities aligned with your strategy.

Tickeron AI Verdict

Based on observable structural factors, Tickeron’s AI would likely assign a modest preference to IHI at present due to its lower expense ratio, larger scale, greater liquidity profile, and diversified positioning across established medical device leaders. GNOM offers compelling thematic depth in genomics but carries higher concentration risk and costs. Investors should weigh these attributes against individual objectives, as probabilistic assessments favor IHI for balanced sector exposure in the current environment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations